PSYC Corporation (PSYC)

[huka]

Beat down hard

[night diff]

Tons of volume today

[huka]

Nice buying here psyc

[cov20]

Coming

[Seasighs]

So, what’s this all about? Are we waiting on News? :)

[night diff]

I'm buying here to January effect

[Seasighs]

I’m on board! $PSYC 2022!!!

[AskMuncher]

$PSYC Psyched Wellness Announces Completion of Its 90 Day Oral Toxicity Study
Press Release | 12/06/2021
Toronto, Ontario--(Newsfile Corp. - December 6, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that further to the please release dated June 28, 2021, the 90-day oral toxicity study has been completed.

KGK, the Company's CRO partner, is now completing the 28-day recovery period, after which a tissue histopathology examination and final report will follow.

A full toxicology report of the 90-day oral repeat-dose study with AME-1 and final histopathology report is expected by mid-January 2022.

"The completion of the 90-day oral toxicity study is a major milestone for Psyched as it provides critical scientific data for the determination of safe dosage levels of AME-1, from which all of our consumer products will be derived as we prepare to launch them to market next year," said Jeffrey Stevens, CEO of Psyched. "Although we are waiting for the final report, we are pleased to share that there was no mortality or morbidity of any of the test rodents during the study and we look forward to providing the full toxicology and histopathology reports early next year."

The study examined the effects of Amanita Muscaria on rodents and involved a repeated dose 90-day oral toxicity study of AME-1. The new data will provide information on the major toxic effects, indicate target organs and the possibility of accumulation of test chemical, and can provide an estimate of a no-observed-adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: [phone]
e: [e-mail]
Website: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the uses and potential benefits of Amanita Muscaria; the Company completing its studies and reports upon the terms and timelines as disclosed herein; and the Company's studies and reports generating the intended information and benefits.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; the continued growth of the Company; the Company completing its studies and reports upon the terms and timelines as disclosed herein; and the Company's studies and reports generating the intended information and benefits.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; the risk that there is no potential benefit of Amanita Muscaria consumption; the risk the Company will be unable to develop its products; the inability of the Company to complete their studies and/or reports on the intended timelines; the inability of the Company to generate reliable or positive reports therefrom; and the risk that the Company will not benefit from the studies and/or reports.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106718

[AskMuncher]

$PSYC Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting
Press Release | 12/01/2021
Toronto, Ontario--(Newsfile Corp. - December 1, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that on November 30, 2021, representatives from the Company and KGK Science, the Company's contract research organization (CRO), presented AME-1, Psyched's proprietary extract of the Amanita Muscaria mushroom, AME-1, to representatives of Health Canada in a pre-submission meeting.

This follows Health Canada's approval announced on November 3, 2021 to add Amanita Muscaria mushroom to the Natural Health Products Ingredients Database (NHPID) of Canada.

"Yesterday's pre-submission meeting was the next important step in positioning the Company to be able to file an application with Health Canada for AME-1 as a Natural Health Product in 2022," said Jeff Stevens, CEO of Psyched Wellness. "The meeting was very encouraging, and we look forward to incorporating Health Canada's comments and suggestions into our plans to bring our Amanita-based CPG products to market next year."

The purpose of a pre-submission meeting is to discuss the evidence required in support of a Class III Product License Application (PLA) or to clarify the type of applications required. Such meetings will:

familiarize assessment staff with the proposed application prior to its arrival and provide a forum to discuss the evidence in order to facilitate its assessment;
establish which studies or scientific evidence the applicant is relying on to support the safety and/or efficacy of the NHP and discuss the adequacy and appropriateness of controls;
provide an opportunity for the applicant to discuss details of the application with Natural and Non-prescription Health Products Directorate (NNHPD) and obtain feedback regarding any areas of concern based on current experience and regulatory requirements; and
provide NNHPD an opportunity to re-align resources, if necessary, to accommodate the arrival of the application.
Pre-submission meetings do not entail a full assessment by NNHPD of the evidence presented and, as such, the outcome does not constitute a regulatory decision by NNHPD, nor will a regulatory decision be issued.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: [phone]
e: [e-mail]
Website: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

[AskMuncher]

$PSYC Psyched Wellness to Present at Grizzle Psychedelics Con on Monday, November 22, 2021
Press Release | 11/17/2021
Toronto, Ontario--(Newsfile Corp. - November 17, 2021) - Psyched Wellness Ltd. (CSE:PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, today announced that Chief Executive Officer, Jeffrey Stevens will participate as a featured speaker in the Grizzle Psychedelics Con 1x1 to be held on Monday, November 22, 2021.

Mr. Stevens will present at 12:40pm ET. The presentation will be livestreamed via this link:

.

For more information about the event, or to schedule a one-on-one meeting with Psyched's management team, please contact KCSA Strategic Communications at [e-mail].

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: [e-mail]
w: http://www.psyched-wellness.com

Investor Contacts:

Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: 978-505-2478
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Psyched Wellness Ltd. current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by Psyched at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information, including, without limitation, (i) the accuracy of the Toxicology Assessment, (ii) the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof, and (iii) the uses and potential benefits of Amanita Muscaria. Given these risks, uncertainties, and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Psyched is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Psyched Wellness Ltd. management's discussion and analysis for the six months ended May 31, 2020 and covering the subsequent period up to July 27, 2020 ("MD&A"), dated July 27, 2020, which is available on Psyched Wellness Ltd. profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103996

[Devils lettuce]

$$$$$$$

[AskMuncher]

$PSYC Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada
Press Release | 11/03/2021
Toronto, Ontario--(Newsfile Corp. - November 3, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that Health Canada has approved the Company's submission to have the Amanita Muscaria mushroom added to The Natural Health Products Ingredients Database (NHPID) of Canada.

Following Psyched's extensive scientific work in testing and data-gathering on the Amanita Muscaria mushroom and its unique extract - AME-1, the Company had submitted the request to Health Canada to add the Amanita Muscaria mushroom (Fly Agaric) to NHPID as a medicinal organism.

Health Canada has approved the request and classified the Amanita Muscaria mushroom as a Natural Health Product under Schedule 1, Item 1 (a fungus) of the Natural Health Products Regulations. To read more about the classification, please visit this link:

http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=18056&lang=eng

Jeff Stevens, CEO of Psyched Wellness said, "The addition of Amanita Muscaria to the NHPID is a significant achievement and is the result of extensive research that Psyched has undertaken to demonstrate its natural medicinal properties. This milestone moves us closer to being able to bring our Amanita-based CPG products to market which we are developing to promote stress relief, relaxation and assist with restful sleeping through the natural calming powers of AME-1."

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: [phone]
e: [e-mail]
Website: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101762

[AskMuncher]

$PSYC Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada
Press Release | 11/03/2021
Toronto, Ontario--(Newsfile Corp. - November 3, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that Health Canada has approved the Company's submission to have the Amanita Muscaria mushroom added to The Natural Health Products Ingredients Database (NHPID) of Canada.

Following Psyched's extensive scientific work in testing and data-gathering on the Amanita Muscaria mushroom and its unique extract - AME-1, the Company had submitted the request to Health Canada to add the Amanita Muscaria mushroom (Fly Agaric) to NHPID as a medicinal organism.

Health Canada has approved the request and classified the Amanita Muscaria mushroom as a Natural Health Product under Schedule 1, Item 1 (a fungus) of the Natural Health Products Regulations. To read more about the classification, please visit this link:

http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredReq.do?id=18056&lang=eng

Jeff Stevens, CEO of Psyched Wellness said, "The addition of Amanita Muscaria to the NHPID is a significant achievement and is the result of extensive research that Psyched has undertaken to demonstrate its natural medicinal properties. This milestone moves us closer to being able to bring our Amanita-based CPG products to market which we are developing to promote stress relief, relaxation and assist with restful sleeping through the natural calming powers of AME-1."

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: [phone]
e: [e-mail]
Website: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101762

[CashCowMoo]

So basically is this company a PR company for news in the medicinal mushroom industry? Doesnt seem like much.

[AskMuncher]

$PSYC PSYC’s Psychedelic Spotlight Debuts First-Of-Its-Kind Video Series for Psychedelics Industry
Press Release | 10/27/2021
Psychedelic Spotlight’s “Spotlight in Focus” Offers a Uniquely Fresh Take on Story Telling for Growing Psychedelics Space

LAKE OSWEGO,OR, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) ("Global" "PSYC" or the "Company"), a leading publicly traded digital media company within the emerging sector of medicinal psychedelics is pleased to announce the debut of its newest video series, "Spotlight in Focus," which the Company contends is the first-of-its-kind for the industry in its presentation and ability to take a deep and informative dive into some of the many highly-relevant subject matters that are helping to shape the new and emerging community of medicinal psychedelics.

Produced and directed by Psychedelic Spotlight's own, Matthew Dunehoo, and hosted by the talented Autumn Tribitt, episode 1 of "Spotlight in Focus" features exclusive interviews with Kate Kincaid, LPC of Tucson Counseling Associates and renowned plant medicine guide, Lane Carlson. The episode is also highlighted by in-studio visits from Dr. Tyler Kjorvestad, MD, Editor in Chief for The Journal of Psychedelic Psychiatry, and healing arts practitioner, Samantha Levi who is also the founder of Phare, a one-of-kind healing arts studio in Kansas City, MO that also serves as the on-site studio and filming location for "Spotlight in Focus."

"As PSYC continues to establish Psychedelic Spotlight as the most recognized and respected media source for the medicinal psychedelics industry, we have to be willing to be bold and innovative with the production and presentation of our content," said Global Trac Solutions, Inc. CEO, David Flores. "This new and emerging industry of ours is so incredibly diverse that I believe much of what is covered by the mainstream media is only a representation of the very top of a surface of what I think is an incredibly fascinating and multifaceted industry. "Spotlight in Focus" is meant to take viewers on a journey beneath that surface and serve as a platform capable of telling some of the most relevant and intriguing stories within our growing community, and in a manner that helps to validate the potential we believe exists with medicinal psychedelics. And as society continues to slowly regain a sense of normalcy, I am excited to expand on our ability to feature more in-studio and on-location interview segments that will help solidify "Spotlight in Focus" as the gold star video series for the medicinal psychedelics industry."

"Our mission is to create a trustworthy forum for empowering the public with the knowledge they can use in their pursuit of wellness, with a reverence for all preceding pioneers and practitioners, and an eye on a sustainably equitable future," said Psychedelic Spotlight Video Producer and Director, Matthew Dunehoo. "The program will emphasize the de-stigmatization of psychedelic practices, substances, and plant medicines and actively seek to provide answers for questions solicited from our audience. We are incredibly grateful to welcome back the talented Ms. Autumn Tribitt as our host. We are also thankful for the wonderful Ms. Samantha Levi for welcoming us into her magnificent healing arts studio, Phare.”

Use this LINK to view episode 1 of “Spotlight in Focus”.

About Global Trac Solutions, Inc. (OTCPink: PSYC)

At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We contend that we are truly the right TRAC to follow.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:

Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
[phone]
[e-mail]
OTCPINK: PSYC

[huka]

Last shake attempt before the run

[kaylex13]

$CMPS the AMZN of Shrooms broke 200ma
$PSYC going to get found.

[lucky__stock]

$PSYC PsyKey will continue to develop additional strategic partnerships as it positions itself in the fast-evolving mushroom markets. With the psychedelic drug market projected to reach the multi-billion-dollar mark by 2027, working with a world-class mycologist and partnering with innovative companies like Zealous, whose goal is commercial production, PsyKey is building on its objectives of long-term growth and increased investor value. https://finance.yahoo.com/news/psykey-inc-announces-discussions-biotechnology-134500665.html

[AskMuncher]

$PSYC Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1
Press Release | 10/07/2021
Toronto, Ontario--(Newsfile Corp. - October 7, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that KGK Science, a licensed contract research organization (CRO) in Canada, is commencing the next pre-clinical trial study on Psyched's key proprietary extract, Amanita Muscaria (AME-1).

The trial will comprise a conditioned placement preference study (CPP) in order to establish any beneficial and or adverse health effects of AME-1, providing critical evidence to determine whether the extract has any abuse potential. The study will compare the basic characteristics of the association of AME-1 treatment in a particular environment, with the association of a different environment in the absence of AME-1.

The CPP paradigm has been used in many fields such as pharmacology, behavioral science and neuroscience research to determine whether consumption of a certain substance can foster psychological or physical dependence.

David Shisel, Chief Operating Officer of Psyched, said: "In conjunction with the other studies the Company is conducting, this trial will bolster Psyched's toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market."

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: [e-mail]
w: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Psyched Wellness Ltd. current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by Psyched at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information, including, without limitation, (i) the accuracy of the previous toxicological assessment, (ii) the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof, (iii) the uses and potential benefits of Amanita Muscaria; and (iv) the completion of the CPP study on the terms outlined this release. Given these risks, uncertainties, and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Psyched is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Psyched Wellness Ltd. management's discussion and analysis for the six months ended May 31, 2021 and covering the subsequent period up to July 28, 2021 ("MD&A"), dated July 28, 2021, which is available on Psyched Wellness Ltd. profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

[highlandernew]

PIERRE BOUCHARD is GREAT ADDITION-to PSYC Team?: https://investorshub.advfn.com/uimage/uploads/2021/9/30/osucdPSYC_PIERRE.png



What are your thoughts about this?

[AskMuncher]

$PSYC PSYC’s Psychedelic Spotlight Nets Over 230K Page Views in August
Press Release | 09/08/2021
Psychedelic Spotlight Continues Emergence as Leading News and Information Resource for Psychedelics Industry

LAKE OSWEGO,OR, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that the Company’s flagship website and media platform, Psychedelic Spotlight, recorded its highest page views to-date with over 233K views in the month of August, and which the Company contends is based on data acquired from Google Analytics.

The website also recorded strong growth rates in the segments of users and sessions with users increasing by a rate of 52%, and sessions increasing by 48% from the previous month (July).

The Company attributes the continued and ongoing growth of Psychedelic Spotlight to both the steady increase in public interest surrounding medicinal psychedelics along with its production and presentation of engaging and thought-provoking industry-focused content which the Company believes is playing an integral role with helping to effectively showcase and interpret the exciting potential it perceives as present within this emerging sector.

“We launched Psychedelic Spotlight almost a year and a half ago and with just a handful of articles and an ambition to establish it as a recognized and trusted resource for an industry we saw a tremendous amount of growth potential in,” said Global Trac Solutions, Inc. CEO, David Flores. “Not only do I think it is fair to say that Psychedelic Spotlight has become a powerful voice for the medicinal psychedelics industry, but in my opinion, it has become a highly valuable platform and resource for some of the many different companies that are continuing to emerge throughout this industry each month. It’s evident to me, based on our impressive growth rate, that our content is resonating quite effectively with the growing audience across this sector. Therefore, not only do we plan to expand upon it in the months to come, but we positively intend to maximize the use of our positioning as a news and information leader within this industry to create new and exciting value-driven opportunities PSYC.”

“We are extremely excited and pleased to see the amazing increases across all of our platforms over the past month and see it as a big indicator as to how the market itself is heating up,” said Director of Psychedelic Spotlight, Sarah Abelsohn. “We have some exciting things in the pipeline with our content and we are excited to see how our community continues to engage with us. And as momentum continues to build, we anticipate seeing more companies and brands who are eager to connect with the ever-expanding audience developing across this industry reach out to us to explore opportunities where they can leverage the use of our platforms to help showcase their story in a truly unique and effective manner.”

About Global Trac Solutions, Inc. (OTCPink: PSYC)

At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We contend that we are truly the right TRAC to follow.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:

Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
[phone]
[e-mail]
OTCPINK: PSYC

[AskMuncher]

$PSYC Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1
Press Release | 09/08/2021
Toronto, Ontario--(Newsfile Corp. - September 8, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce the Company, in collaboration with KGK, a licensed CRO in Canada, is commencing the next preclinical trial study on Amanita Muscaria Extract (AME-1). The trial will comprise a neurobehavioral study focusing on determining the neurotoxicity effects of AME-1 on functional and motor activity, and in conjunction with the other toxicity studies, will provide scientific evidence for the efficacy and safety of AME-1. The study will involve non-invasive observational measures assessing neurological, motor and functional integrity, which are critical indicators to measuring neural function.

Brian Tancowny, Scientific Advisor to Psyched Wellness, stated: "This study is another key step in understanding the effects of (AME-1), in pursuit of a safe dosing regimen for human consumption. The results of this study will further enhance the Company's knowledge of AME-1 and further identify in a scientific setting any behavioral and neurological functional changes with the use of AME-1."

Jeff Stevens, CEO of Psyched, said: "This preclinical trial study moves the Company closer to being able to market our products in 2022 which are aimed at helping relaxation, stress relief, and better sleep. Psyched will be the first company to complete the extensive scientific trials on Amanita Muscaria in order to position AME-1 as the first extract of the fungi that is legal for human consumption in the health and wellness markets."

For further information, please contact:
Jeffrey Stevens
Chief Executive Officer Psyched Wellness Ltd.
t: [phone]
e: [e-mail]

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

About CannaLabs Science Inc.:

CannaLabs Science Inc. is a Canadian-based, Health Canada licensed analytical laboratory. The Company's state of the art lab specializes in analytical testing for the cannabis, natural health products and pharmaceutical industries. Since inception, CannaLabs has collaborated with various Clients to develop scientific methods and validations to support product development, test raw materials and finished products, and develop and conduct characterization and stability studies.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to (i) Cannalabs performing stability tests on the Company's AME-1 on the terms and conditions outlined in this press release, (ii) the safety of AME-1 for human consumption, (iii) the Company's expectations with respect to the commercialization of AME-1, (iv) and the Company's expectation to develop a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with stress relief, relaxation, and restful sleeping. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended, including, Cannalab's ability to complete the stability tests on the terms and conditions outlined this release and develop the new testing method for the material, the stability tests producing sufficient results to allow Company to determine the expiration dates and storage conditions for the final product, the Company's ability to commercialize the products which depends on the Company receiving the necessary raw materials needed to complete the research and market the products, the Company having the resources to complete the research and prepare and file the necessary regulatory applications needed to commercialize the product, the products having the expected impact on stress relief, relaxation, and sleeping.

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

[AskMuncher]

$PSYC Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1
Press Release | 08/17/2021
Toronto, Ontario--(Newsfile Corp. - August 17, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has submitted applications to the United States Patent and Trademark office, for four further provisional patents surrounding the Company's flagship product - AME-1.

The applications were submitted on August 11, 2021 as such:

App US63/232,144: THERAPEUTIC COMPOSITIONS OF AMANITA MUSCARIA EXTRACTS AND THEIR USE FOR ANXIETY, SUBSTANCE USE, AND SLEEP DISORDERS, AND FOR THE IMPROVEMENT OF OVERALL MENTAL HEALTH AND WELLBEING;

App US63/232,152: THERAPEUTIC COMPOSITIONS OF AMANITA MUSCARIA EXTRACTS AND THEIR USE FOR PAIN, INFLAMMATION, AND IMMUNE DISORDERS, AND FOR THE IMPROVEMENT OF OVERALL PHYSICAL HEALTH AND WELLNESS;

App US63/232,157: THERAPEUTIC COMPOSITIONS OF MUSCIMOL AND MUSCARINE AND THEIR ANALOGS AND THEIR USE FOR ANXIETY, SUBSTANCE USE, AND SLEEP DISORDERS, AND FOR THE IMPROVEMENT OF OVERALL MENTAL HEALTH AND WELLBEING;

App US63/232,160: THERAPEUTIC COMPOSITIONS OF MUSCIMOL AND MUSCARINE AND THEIR ANALOGS AND THEIR USE FOR PAIN, INFLAMMATION, AND IMMUNE DISORDERS, AND FOR THE IMPROVEMENT OF OVERALL PHYSICAL HEALTH AND WELLNESS;

Jeff Stevens, CEO of Psyched Wellness, said, "The filing of these patents marks another important milestone in the execution of Psyched's strategy, and moves us closer to being able to bring our products to market. We believe AME-1 will have a sustainable commercial and societal impact with its power to help stress relief, relaxation and restful sleeping."

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: [phone]
e: [e-mail]
w: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

For media relations, please contact:
Anne Graf
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Psyched Wellness Ltd. current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by Psyched at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information, including, without limitation, (i) the accuracy of the Toxicology Assessment, (ii) the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof, and (iii) the uses and potential benefits of Amanita Muscaria. Given these risks, uncertainties, and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Psyched is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Psyched Wellness Ltd. management's discussion and analysis for the six months ended May 31, 2020 and covering the subsequent period up to July 27, 2020 ("MD&A"), dated July 27, 2020, which is available on Psyched Wellness Ltd. profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment. The Company believes that the data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this news release or ascertained the underlying assumptions relied upon by such sources.

[AskMuncher]

$PSYC Psyched Wellness Enters into a Service Agreement with CannaLabs to Begin Stability Tests on AME-1
Press Release | 07/26/2021
Toronto, Ontario--(Newsfile Corp. - July 26, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the Company has entered into a service agreement with CannaLabs, a Canadian, London-based laboratory services company, licensed by Health Canada.

According to the agreement, Psyched Wellness will use the services of CannaLabs to perform stability tests on the Company's AME-1. The stability tests will help the Company to determine the expiration dates and storage conditions for the final product - AME-1.

In addition, CannaLabs will develop for the Company a new testing method for the raw material to help the Company differentiate between other species and toxins, thus creating a safe and scientific protocol for acceptable raw material.

All intellectual property and/or operational tools that will be developed during the execution of this service agreement will be the sole property of Psyched Wellness.

"Having CannaLabs working closely on the production side of AME-1 further enhances the product quality and validity ensuring AME-1 is a safe and viable product for human consumption," said Brian Tancowny Psyched Wellness's Head of Pre-Clinical Studies.

"We are thrilled to be working closely with Psyched Wellness and leading the analysis of AME-1," said Liliana Santamaria, Director and Vice President of Lab Operations, CannaLabs.

"After many months of pre clinical trials and other scientific work that is still ongoing, we have great confidence in our AME-1," said David Shisel COO of Psyched Wellness. "Commencing the stability tests on the AME-1 is a big step that gets us closer to market."

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: [phone]
Email: [e-mail]

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

About CannaLabs Science Inc.:

CannaLabs Science Inc. is a Canadian-based, Health Canada licensed analytical laboratory. The Company's state of the art lab specializes in analytical testing for the cannabis, natural health products and pharmaceutical industries. Since inception, CannaLabs has collaborated with various Clients to develop scientific methods and validations to support product development, test raw materials and finished products, and develop and conduct characterization and stability studies.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to (i) CannaLabs performing stability tests on the Company's AME-1 on the terms and conditions outlined in this press release, (ii) the safety of AME-1 for human consumption, (iii) the Company's expectations with respect to the commercialization of AME-1, (iv) and the Company's expectation to develop a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with stress relief, relaxation, and restful sleeping. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended, including, CannaLab's ability to complete the stability tests on the terms and conditions outlined this release and develop the new testing method for the material, the stability tests producing sufficient results to allow Company to determine the expiration dates and storage conditions for the final product, the Company's ability to commercialize the products which depends on the Company receiving the necessary raw materials needed to complete the research and market the products, the Company having the resources to complete the research and prepare and file the necessary regulatory applications needed to commercialize the product, the products having the expected impact on stress relief, relaxation, and sleeping.

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

[sharky]

PSYC news:


PSYC Looks to Acquire Additional Equity in Digital Mental Health Startup, PsycheDev Inc.
July 14 2021 - 08:30AM
InvestorsHub NewsWire

Share On Facebook


PSYC Looks to Acquire Additional Equity in Digital Mental Health Startup, PsycheDev Inc.

PSYC and PsycheDev Inc. Begin Ramping-Up Product Launch Efforts

LAKE OSWEGO,OR -- July 14, 2021 -- InvestorsHub NewsWire -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that the Company has reached an agreement in principle with PsycheDev Inc. (“PsycheDev”) to acquire up to an additional 5% in equity of PsycheDev through a series of additional investments throughout the remainder of the 2021 fiscal year.

The agreement, in principle, between the companies comes as progress with the development of PsycheDev’s digital mental health application continues to move forward and keeping them on course for an intended minimum viable product launch by the 4th quarter of this year, and as they look to close an additional private equity financing deal in this or the final quarter.

In January, PSYC acquired a 15% equity stake in PsycheDev through an executed Joint Venture Partnership Agreement and investment into the PsycheDev company. PSYC intends to now focus its efforts on acquiring up to an additional 5% equity stake in PsycheDev while also working closely with them to develop and implement their forthcoming go-to-market strategy for the app.

“We are incredibly pleased with the progress of the PsycheDev app and for the opportunity to expand our equity stake in their company,” said Global Trac Solutions, Inc. CEO, David Flores. “Since our first introduction to the PsycheDev company in late 2020, we have believed in the value potential of their company which is why we were proud to become early investors in their concept. The digital mental health sector, in my opinion, only continues to expand as more and more fascinating digital tools hit the market. Justin (Justin Roy, CEO of PsycheDev Inc.) has demonstrated, in my opinion, incredible leadership and dedication over the past several months in helping to move the app through the different phases of development, assembling an impressive team of experienced mental health professionals, and with securing the additional financing necessary to bring his concept to fruition.”

“With Global Trac Solutions gaining more and more traction through their digital platforms, we are more than happy to expand our partnership and to offer them an additional 5% equity stake in PsycheDev,” Said PsycheDev Inc. Founder and CEO, Justin Roy. “The sustained growth from Psychedelic Spotlight's audience combined with their team's marketing expertise is very valuable to us, especially at this stage, and so we strongly believe in their ability to help us solidify our positioning. We're looking forward to this continued collaboration and to the exciting launch ahead. We are also constantly recruiting test users and would like to take this opportunity to welcome anyone interested in early testing to contact us or Psychedelic Spotlight."

“In the coming the months, we plan to leverage the use of our Psychedelic Spotlight platform to help identify and build a target market for PsycheDev and play a vital role in what we expect will be a successful product launch,” said Flores.

About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, we believe investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We are dedicated to a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We contend that we are truly the right TRAC to follow.

Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
[phone]
[e-mail]
OTCPINK: PSYC


$PSYC

[Maws]

Thank you for all the cheap shares, did you guys see that almost 2mil buy at .0118 lucky lucky fill. ;)

[Twotone]

Good news:

MAGIC MUSHROOMS could be used to treat depression: Psychedelic compound increases the number of neural connections in the brain by 10%, study finds
Psilocybin, a drug found in 'magic mushrooms' may be able to reduce the effects of depression
Drug strengthened and increased the number of neural connections in mice during study
The drug could be effective for over a month, as brain connections in mice remained strong long term
Drug was previously used in some spiritual ceremonies in indigenous American cultures
By MANSUR SHAHEEN FOR DAILYMAIL.COM

PUBLISHED: 13:35 EDT, 5 July 2021 | UPDATED: 13:35 EDT, 5 July 2021

[TimeItRight]

Been in this company since way back in the day. Looks like we are never gonna get back those losses from the 100 to 1 reverse merger under useless Luna CEO leader and failure of weed endeavor.

[BlazingStocks]

Nice green close on over half of the $PSYC average volume... closing just below the high of the day.

[BlazingStocks]

Thanks for sharing this amazing $PSYC News...it's not on Yahoo Finance.

[AskMuncher]

$PSYC Psyched Wellness Commences Next Pre-Clinical Study on AME-1
Press Release | 06/28/2021
Toronto, Ontario--(Newsfile Corp. - June 28, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company and its CRO partner, KGK Science, has commenced the next preclinical study, a 90-day oral toxicity study of AME-1.

This new study will examine the effects of Amanita Muscaria on rodents and will involve a repeated dose 90-day oral toxicity study of AME-1. It aims to provide information on the possible anatomical responses which may arise from repeated exposure over a period of time, covering post-weaning maturation and growth into adulthood of the test animals. The study will provide information on the major toxic effects, indicate target organs and the possibility of accumulation of test chemical, and can provide an estimate of a no-observed-adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure.

"Once we have the data from both the 14-day oral toxicity study and 90-day oral toxicity study, we will be able to confidently determine safe dosage levels for AME-1," says Brian Tancowny, scientific advisor for Psyched Wellness.

"The data from these studies will provide Psyched with the foundational knowledge from which all of our consumer products will be derived. This is a very exciting time for the Company, as we look forward to sharing the data from these studies in the near future and continuing to execute on our near- and long-term business objectives," says Jeff Stevens, CEO of the Company.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
t: 647-400-8494
e: [e-mail]
w: http://www.psyched-wellness.com

Investor Contacts:
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: [phone]
e: [e-mail]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information and Statements

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Psyched Wellness Ltd. current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by Psyched at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information, including, without limitation, (i) the terms, scope and completion of the 90-day oral toxicity study will occur as per the details in this release, (ii) the study yielding the results necessary for management of the Company to make the conclusions it expects to make regarding the toxicity and safe dosage amounts of Amanita Muscaria, (iii) the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof, and (iv) the uses and potential benefits of Amanita Muscaria. Some of the risks that could cause the results expressed in forward-looking statements relating to the Company's plans in respect of the study to differ are the Company not having the necessary materials and resources to complete the study, and the studies not yielding the sort of information expected. Given these risks, uncertainties, and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Psyched is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Psyched Wellness Ltd. management's discussion and analysis for the six months ended May 31, 2020 and covering the subsequent period up to July 27, 2020 ("MD&A"), dated July 27, 2020, which is available on Psyched Wellness Ltd. profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment. The Company believes that the data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third party sources referred to in this news release or ascertained the underlying assumptions relied upon by such sources.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88684

[BlazingStocks]

Good morning sharky! Already 1/3 of the $PSYC 10-day average volume in the first hour!

[sharky]

GM all, plenty if room to run here IMO



$PSYC

[BlazingStocks]

$PSYC trading at over 80% of its average volume with 3.5 hours left in the day! Green is still in sight.

[BlazingStocks]

Good morning sharky and $PSYC!

0.017s up and hit with a tight BID!

[sharky]

GM all .017's up



$PSYC

[BlazingStocks]

$PSYC needs to close over this resistance point of approximately 0.0169...

[BlazingStocks]

Looking forward to seeing the $PSYC Audited Financials.

Over the next several weeks, the Company plans to work in collaboration with M&K and the Company’s accounting firm, SGT Enterprises, Inc., to conduct a full audit of its 2020 financials. Previously, the Company filed 2017, 2018, and 2019 audited annual financials as well as its quarterly reports, in addition to unaudited 2020 annual financials as well as the initial quarterly report for 2021.

[BlazingStocks]

This measure us important for $PSYC, The State of California, and America...

“We have a mental health crisis in this country and California is not immune,” Said Senator Wiener about SB 519 in his exclusive interview with Psychedelic Spotlight. “We know that psychedelics can have significant benefits with people struggling with addiction and mental health challenges. It’s not a global solution. We need the FDA to act and we need a lot of other things to happen, but this is one step we can take.”

[WallStreetSurvivor]

$PSYC Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics https://finance.yahoo.com/news/psyc-interviews-ca-senator-scott-123000341.html

[BlazingStocks]

Interesting interview...Discussing Efforts to Legalize Psychedelics.

$PSYC News June 23, 2021

Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics PSYC Examines Senate Bill 519 Which Aims to Decriminalize Psychedelics in California https://finance.yahoo.com/news/psyc-interviews-ca-senator-scott-123000341.html

[WallStreetSurvivor]

$PSYC News! Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics https://finance.yahoo.com/news/psyc-interviews-ca-senator-scott-123000341.html

[sharky]

PSYC news: PSYC Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics
June 23 2021 - 08:30AM
InvestorsHub NewsWire

Share On Facebook


PSYC Interviews CA Senator Scott Wiener to Discuss Efforts to Legalize Psychedelics

PSYC Examines Senate Bill 519 Which Aims to Decriminalize Psychedelics in California

LAKE OSWEGO,OR -- June 23, 2021 -- InvestorsHub NewsWire -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that the Company’s CEO, David Flores, recently sat down with CA Senator Scott Wiener (D-San Francisco) as part of an exclusive Psychedelic Spotlight interview to discuss Senate Bill 519 which aims to decriminalize the possession and sharing of certain hallucinogenic/psychedelic substances within the state.

The measure, which was introduced by Senator Wiener earlier this year, cleared its first major hurdle this month when it was passed in a 21-16 vote by the state Senate resulting in it moving on to the state Assembly for review.
And while the Company recognizes the challenge the measure still faces with attempting to successfully move through the California Assembly, and that there is no guarantee of it doing so, it believes the early success the measure has achieved thus far with clearing the state Senate is another encouraging sign of the positive momentum that continues to build behind psychedelics throughout society.

“When the decision was made to reposition PSYC into to this emerging sector of medicinal psychedelics, we understood the long road and challenges the industry still had in front of it in terms of its ability to evolve into a full-fledged industry that would be received with open arms by society,” Said Global Trac Solutions, Inc. CEO, David Flores. “However, much like we watched unfold in the cannabis space over the last several years, progress is often times observed through the achievement of what on the surface may appear to be small milestones, but in actuality are a part of a series of milestones that can potentially lead to very big changes.”

“In my opinion, SB 519 has the potential to serve as an important catalyst for the psychedelic movement across the country,” Flores continued. “I commend the dedication Senator Wiener has committed towards helping guide this measure through the state Senate and look forward to staying in contact with him and his team to monitor its progress over the coming months.”

“We have a mental health crisis in this country and California is not immune,” Said Senator Wiener about SB 519 in his exclusive interview with Psychedelic Spotlight. “We know that psychedelics can have significant benefits with people struggling with addiction and mental health challenges. It’s not a global solution. We need the FDA to act and we need a lot of other things to happen, but this is one step we can take.”

The Company encourages those interested in viewing the full interview with Senator Wiener to visit Psychedelic Spotlight or its YouTube page.

About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
[phone]
[e-mail]


$PSYC

[sharky]

Just need to lock the float here IMO



$PSYC

[BlazingStocks]

Nice BID, more than half of the total volume today.

[sharky]

PSYC 52 week high .11



$PSYC

[BlazingStocks]

That's great News for $PSYC...

[huka]

In at .0165 and bidding.. this run should be psychedelic for PSYC

[sharky]

PSYC news: PSYC Engages Auditing Firm for Audit of 2020 Financials
June 21 2021 - 08:30AM
InvestorsHub NewsWire


PSYC Engages Auditing Firm for Audit of 2020 Financials

LAKE OSWEGO,OR -- June 21, 2021 -- InvestorsHub NewsWire -- Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a leading publicly traded digital media company within the emerging sector of medicinal psychedelics, is pleased to announce that it has engaged the services of M&K CPAS PLLC (“M&K”), a full service CPA firm based in Houston, TX, with the intent of bringing the Company’s audited financials current up through December 31, 2020.

Over the next several weeks, the Company plans to work in collaboration with M&K and the Company’s accounting firm, SGT Enterprises, Inc., to conduct a full audit of its 2020 financials. Previously, the Company filed 2017, 2018, and 2019 audited annual financials as well as its quarterly reports, in addition to unaudited 2020 annual financials as well as the initial quarterly report for 2021.

“Ensuring that PSYC is primed and ready to capitalize on every potential value-driven opportunity we may encounter as we continue to immerse ourselves further within the medicinal psychedelics industry is, without question, a top priority of mine,” Said Global Trac Solutions, Inc. CEO, David Flores. “And though nothing at this time is definitive and there can be no assurances of the completion of any filing, I recognize the importance in keeping ourselves as prepared as possible to file our Form 10 registration statement which will make us a reporting company pursuant to the Securities Exchange Act of 1934, a core focus of our business strategy.”

“In my opinion, having our 2017, 2018 and 2019 financials already audited places us in a rather advantageous position and one that I believe is especially unique for a Pink Sheet company,” Flores continued. “My intent in providing our audited annual financials (in place of the current unaudited annual financials) for the year ended 2020 is to enhance the full and fair disclosure of information regarding our Company as well as proceed with the implementation of our strategy of becoming a reporting company while simultaneously continuing to strengthen our position as a public company in what I believe is becoming one of the most exciting and opportunity-filled industries today.”

The Company intends to keep its shareholders apprised of its progress with the audit of its year end 2020 annual financials.

About Global Trac Solutions, Inc. (OTCPink: PSYC)
At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.
PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19 and the success of the current vaccine distribution, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:
Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
[phone]
[e-mail]
OTCPINK: PSYC



$PSYC

[WallStreetSurvivor]

$PSYC News! PSYC CEO Discusses Increasing Audience, Recent Investments in The Medicinal Psychedelic Space, and Upcoming Financial Audit with The Stock Day Podcast
https://finance.yahoo.com/news/psyc-ceo-discusses-increasing-audience-123000122.html